Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAZALS: dazucorilant in amyotrophic lateral sclerosis
2024-514082-19-00Phase 2Authorised
- Sponsor
- Corcept Therapeutics
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Dazucorilant with Placebo (2 arms). Primary endpoints: Change from baseline to Week 24 in ALSFRS-R total score, Incidence of AEs, SAEs, treatment-related AEs, AEs by severity, and death due to AEs and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-514082-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514082-19-00.